C5b-9 Glomerular Deposits Are Associated With Poor Renal Survival in Membranous Nephropathy

Couser, 2017, Primary membranous nephropathy, Clin J Am Soc Nephrol, 12, 983, 10.2215/CJN.11761116 Salant, 1980, A new role for complement in experimental membranous nephropathy in rats, J Clin Invest, 66, 1339, 10.1172/JCI109987 Perkinson, 1985, Membrane attack complex deposition in experimental glomerular injury, Am J Pathol, 120, 121 Cybulsky, 1950, The membrane attack complex in complement-mediated glomerular epithelial cell injury: formation and stability of C5b-9 and C5b-7 in rat membranous nephropathy, J Immunol, 137, 1511, 10.4049/jimmunol.137.5.1511 Lateb, 2019, Anti-PLA2R1 antibodies containing sera induce in vitro cytotoxicity mediated by complement activation, J Immunol Res, 2019 Donadio, 1988, Idiopathic membranous nephropathy: the natural history of untreated patients, Kidney Int, 33, 708, 10.1038/ki.1988.56 Goutaudier, 2019, C5b9 deposition in glomerular capillaries is associated with poor kidney allograft survival in antibody-mediated rejection, Front Immunol, 10, 235, 10.3389/fimmu.2019.00235 2012, KDIGO clinical practice guideline for glomerulonephritis, Kidney Int Suppl, 86 Ronco, 2019, Molecular pathogenesis of membranous nephropathy, Annu Rev Pathol, 15, 287, 10.1146/annurev-pathol-020117-043811 Ma, 2013, The role of complement in membranous nephropathy, Semin Nephrol, 33, 531, 10.1016/j.semnephrol.2013.08.004 Mollnes, 1985, Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma, Scand J Immunol, 22, 183, 10.1111/j.1365-3083.1985.tb01870.x Nangaku, 1998, Complement regulatory proteins in glomerular diseases, Kidney Int, 54, 1419, 10.1046/j.1523-1755.1998.00130.x Kerjaschki, 1997, Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis, J Clin Invest, 100, 2303, 10.1172/JCI119768 Neale, 1994, Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen, J Clin Invest, 94, 1577, 10.1172/JCI117499 Exner, 1996, Lipoproteins accumulate in immune deposits and are modified by lipid peroxidation in passive Heymann nephritis, Am J Pathol, 149, 1313 Leenaerts, 1995, Active Heymann nephritis in complement component C6 deficient rats, Kidney Int, 47, 1604, 10.1038/ki.1995.224 Spicer, 2007, Induction of passive Heymann nephritis in complement component 6-deficient PVG rats, J Immunol, 179, 172, 10.4049/jimmunol.179.1.172 Meyer-Schwesinger, 2011, Nephrotic syndrome and subepithelial deposits in a mouse model of immune-mediated anti-podocyte glomerulonephritis, J Immunol, 187, 3218, 10.4049/jimmunol.1003451 Tomas, 2016, Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy, J Clin Invest, 126, 2519, 10.1172/JCI85265 Tomas, 2017, A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy, J Am Soc Nephrol, 28, 3262, 10.1681/ASN.2017010030 Herwig, 2019, Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes, J Am Soc Nephrol, 30, 824, 10.1681/ASN.2018090941 Škoberne, 2014, Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen, Eur J Clin Investig, 44, 753, 10.1111/eci.12292 Brenchley, 1992, Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy, Kidney Int, 41, 933, 10.1038/ki.1992.143 Kon, 1995, Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy, Kidney Int, 48, 1953, 10.1038/ki.1995.496 Appel, 2002, Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy, J Am Soc Nephrol, 13, 668A Zipfel, 2019, Complement inhibitors in clinical trials for glomerular diseases, Front Immunol, 10, 2166, 10.3389/fimmu.2019.02166 Cameron, 1990, The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party, Q J Med, 74, 133 Cattran, 1989, A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy, N Engl J Med, 320, 210, 10.1056/NEJM198901263200403 Miller, 2000, Use of mycophenolate mofetil in resistant membranous nephropathy, Am J Kidney Dis, 36, 250, 10.1053/ajkd.2000.8968 Fervenza, 2019, Rituximab or cyclosporine in the treatment of membranous nephropathy, N Engl J Med, 381, 36, 10.1056/NEJMoa1814427 Rovin, 2021, KDIGO 2021 clinical practice guideline for the management of glomerular diseases, Kidney Int, 100, S1, 10.1016/j.kint.2021.05.021